ARTES Biotechnology and Burnet Institute have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI).
The project will use exciting novel technology developed at the Burnet Institute, by Deputy-Director, Associate Professor David Anderson and colleagues. ARTES holds the international patent rights and adapted the platform to vaccine production (known as the Metavax platform).
Purified vaccine antigens (Pfs25 and Pfs230) will be produced as virus-like particles (VLPs, a type of nano-particle) for testing in laboratory studies.
The VLPs will be taken up by immune cells to prime and prepare the immune system to fight malaria.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with Baxter Healthcare
Related reports: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity